Yoshinobu Konishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yoshinobu Konishi has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Akifumi Takaori-Kondo
Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
17 shared publications - Kenta Terai
Department of Histology Graduate School of Biomedical Sciences Tokushima University Kuramoto-cho Tokushima 770-8503 Japan
16 shared publications - Michiyuki Matsuda
Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
16 shared publications Choji Oki
15 shared publications- Hiroshi Ichise
Lymphocyte Biology Section, Laboratory of Immune System Biology, NIAID, NIH
15 shared publications - Shinya Tsukiji
Nagoya Institute of Technology
15 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Springer Nature in Research Square
Myeloma Precursors Erode Durable Immunity: Results of the IMPACT study
Multiple myeloma (MM) is a plasma cell malignancy marked by profound immune dysfunction and substantial infection-related mortality. MM is preceded by the asymptomatic precursor states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), yet whether these patients can mount effective immune responses remains unknown. In this prospective observational study of 731 individuals recruited nationwide through Dana-Farber Cancer Institute, we used SARS-CoV-2 vaccination as a standardized immunological challenge alongside childhood vaccine serology. We show that precursor myeloma is associated with broad dysfunction across innate and adaptive immunity, including accelerated antibody waning, erosion of childhood vaccine titers, impaired antigen-specific T cell expansion, and blunted innate activation. Mechanistically, we link these defects to tumor burden-dependent APRIL depletion and downregulation of APRIL-responsive pathways in normal plasma cells, validated in an independent cohort. These findings have direct implications for cancer vaccine development, immunotherapy, and infection management in early-stage hematologic malignancies.
- 14 April 2026
- Published by Springer Nature in Research Square
Open AccessMyeloma Precursors Erode Durable Immunity: Results of the IMPACT study
Multiple myeloma (MM) is a plasma cell malignancy marked by profound immune dysfunction and substantial infection-related mortality. MM is preceded by the asymptomatic precursor states monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), yet whether these patients can mount effective immune responses remains unknown. In this prospective observational study of 731 individuals recruited nationwide through Dana-Farber Cancer Institute, we used SARS-CoV-2 vaccination as a standardized immunological challenge alongside childhood vaccine serology. We show that precursor myeloma is associated with broad dysfunction across innate and adaptive immunity, including accelerated antibody waning, erosion of childhood vaccine titers, impaired antigen-specific T cell expansion, and blunted innate activation. Mechanistically, we link these defects to tumor burden-dependent APRIL depletion and downregulation of APRIL-responsive pathways in normal plasma cells, validated in an independent cohort. These findings have direct implications for cancer vaccine development, immunotherapy, and infection management in early-stage hematologic malignancies.
- 8 August 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (9) , 1595-1611
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
Multiple myeloma is a bone marrow (BM) plasma cell malignancy preceded by precursor conditions. BM biopsies are conducted infrequently and can yield inconclusive results due to technical limitations. Profiling circulating tumor cells (CTCs) may enable noninvasive routine clinical assessments but remains challenging. Here, to address this, we describe a single-cell sequencing workflow to interrogate few tumor cells (SWIFT-seq), and employ single-cell RNA sequencing and B cell receptor sequencing on paired BM and CTCs from 101 patients and healthy donors. We establish a sequencing-based CTC enumeration strategy and develop a CTC classifier to infer cytogenetic abnormalities. Additionally, we leverage expression profiling to measure tumor proliferative index in CTCs, and demonstrate that clonal dynamics can be captured in CTCs. Last, we propose a circulatory dynamics model whereby tumor burden, proliferation, cytogenetics and a circulatory capacity signature influence CTC burden. Overall, SWIFT-seq may advance blood-based myeloma diagnostics, surveillance and prognostication, and reveal biological mechanisms of tumor dissemination.
- 8 August 2025
- Published by Springer Nature in Nature Cancer
- Vol. 6 (9) , 1595-1611
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
Multiple myeloma is a bone marrow (BM) plasma cell malignancy preceded by precursor conditions. BM biopsies are conducted infrequently and can yield inconclusive results due to technical limitations. Profiling circulating tumor cells (CTCs) may enable noninvasive routine clinical assessments but remains challenging. Here, to address this, we describe a single-cell sequencing workflow to interrogate few tumor cells (SWIFT-seq), and employ single-cell RNA sequencing and B cell receptor sequencing on paired BM and CTCs from 101 patients and healthy donors. We establish a sequencing-based CTC enumeration strategy and develop a CTC classifier to infer cytogenetic abnormalities. Additionally, we leverage expression profiling to measure tumor proliferative index in CTCs, and demonstrate that clonal dynamics can be captured in CTCs. Last, we propose a circulatory dynamics model whereby tumor burden, proliferation, cytogenetics and a circulatory capacity signature influence CTC burden. Overall, SWIFT-seq may advance blood-based myeloma diagnostics, surveillance and prognostication, and reveal biological mechanisms of tumor dissemination.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Prostaglandin E2 (PGE2) promotes tumor progression through evasion of antitumor immunity. In stark contrast to cyclooxygenase-dependent production of PGE2, little is known whether PGE2 secretion is regulated within tumor tissues. Here, we show that VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in PGE2 secretion and subsequent immune evasion in the early stages of tumorigenesis. Ca2+ transients caused cPLA2 activation and triggered the arachidonic acid cascade. Ca2+ transients were monitored as the surrogate marker of PGE2 secretion. Intravital imaging of BrafV600E mouse melanoma cells revealed that the proportion of cells exhibiting Ca2+ transients is markedly higher in vivo than in vitro. The TXA2 receptor was indispensable for the Ca2+ transients in vivo, high intratumoral PGE2 concentration, and evasion of antitumor immunity. Notably, treatment with a VEGF receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues. These results identify the VEGF–TXA2 axis as a critical promoter of PGE2-dependent tumor immune evasion, providing a molecular basis underlying the immunomodulatory effect of anti-VEGF therapies.Significance:This study identifies the VEGF–TXA2 axis as a potentially targetable regulator of PGE2 secretion, which provides novel strategies for prevention and treatment of multiple types of malignancies.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Prostaglandin E2 (PGE2) promotes tumor progression through evasion of antitumor immunity. In stark contrast to cyclooxygenase-dependent production of PGE2, little is known whether PGE2 secretion is regulated within tumor tissues. Here, we show that VEGF-dependent release of thromboxane A2 (TXA2) triggers Ca2+ transients in tumor cells, culminating in PGE2 secretion and subsequent immune evasion in the early stages of tumorigenesis. Ca2+ transients caused cPLA2 activation and triggered the arachidonic acid cascade. Ca2+ transients were monitored as the surrogate marker of PGE2 secretion. Intravital imaging of BrafV600E mouse melanoma cells revealed that the proportion of cells exhibiting Ca2+ transients is markedly higher in vivo than in vitro. The TXA2 receptor was indispensable for the Ca2+ transients in vivo, high intratumoral PGE2 concentration, and evasion of antitumor immunity. Notably, treatment with a VEGF receptor antagonist and an anti-VEGF antibody rapidly suppressed Ca2+ transients and reduced TXA2 and PGE2 concentrations in tumor tissues. These results identify the VEGF–TXA2 axis as a critical promoter of PGE2-dependent tumor immune evasion, providing a molecular basis underlying the immunomodulatory effect of anti-VEGF therapies.Significance:This study identifies the VEGF–TXA2 axis as a potentially targetable regulator of PGE2 secretion, which provides novel strategies for prevention and treatment of multiple types of malignancies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 4 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s with or without treatment of a VEGFR inhibitor, motesanib. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s with or without treatment of a VEGFR inhibitor, motesanib. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 4C. Images were acquired every 6 seconds for 40 minutes. Motesanib was intravenously administered at 10 minutes. At only about 20 minutes after administration, the Ca2+ transients were significantly suppressed. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 4 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s with or without treatment of a VEGFR inhibitor, motesanib. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s with or without treatment of a VEGFR inhibitor, motesanib. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 4C. Images were acquired every 6 seconds for 40 minutes. Motesanib was intravenously administered at 10 minutes. At only about 20 minutes after administration, the Ca2+ transients were significantly suppressed. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Supplementary Method, Reference, Figures 1-8, Tables 1-2
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Supplementary Method, Reference, Figures 1-8, Tables 1-2
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 3 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s [parental, Gnaq-/-, and Gnaq-/- cells introduced with Gnaq (Gnaq-/- + Gnaq)]. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 1E. Images were acquired every 3 seconds for 15 minutes. From left to right: parental melanoma, Gnaq-/- melanoma, and Gnaq-/- melanoma cells introduced with Gnaq (Gnaq-/- + Gnaq). Genetic ablation of Gnaq abolished active Ca2+ transients observed in parental cells, which was restored by the introduction of Gnaq in Gnaq-/- melanoma. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 3 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s [parental, Gnaq-/-, and Gnaq-/- cells introduced with Gnaq (Gnaq-/- + Gnaq)]. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 1E. Images were acquired every 3 seconds for 15 minutes. From left to right: parental melanoma, Gnaq-/- melanoma, and Gnaq-/- melanoma cells introduced with Gnaq (Gnaq-/- + Gnaq). Genetic ablation of Gnaq abolished active Ca2+ transients observed in parental cells, which was restored by the introduction of Gnaq in Gnaq-/- melanoma. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 1 Live imaging of MDCK cells expressing the PKA biosensor. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Live imaging of MDCK cells expressing the PKA biosensor. BrafV600E melanoma cells expressing the DREADD hM3 were stimulated by 1 μM CNO treatment at 60 seconds. PKA activation in surrounding MDCK cells was observed 30 seconds after stimulation. Scale bar = 100 µm. Times are shown in minutes (m) and seconds (s).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 Live imaging of MDCK cells expressing the PKA biosensor. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Live imaging of MDCK cells expressing the PKA biosensor. BrafV600E melanoma cells expressing the DREADD hM3 were stimulated by 1 μM CNO treatment at 60 seconds. PKA activation in surrounding MDCK cells was observed 30 seconds after stimulation. Scale bar = 100 µm. Times are shown in minutes (m) and seconds (s).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 2 Live imaging of BrafV600E melanoma cells expressing GCaMP6s in vivo and in vitro. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Live imaging of BrafV600E melanoma cells expressing GCaMP6s in vivo and in vitro. Pseudo colors represent the fluorescence intensity as in Figure 1C. Images were acquired every 6 seconds for 20 minutes. A small population of tumor cells continuously shows active Ca2+ transients repeatedly in vivo, but not in vitro. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 2 Live imaging of BrafV600E melanoma cells expressing GCaMP6s in vivo and in vitro. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Live imaging of BrafV600E melanoma cells expressing GCaMP6s in vivo and in vitro. Pseudo colors represent the fluorescence intensity as in Figure 1C. Images were acquired every 6 seconds for 20 minutes. A small population of tumor cells continuously shows active Ca2+ transients repeatedly in vivo, but not in vitro. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Supplementary Method, Reference, Figures 1-8, Tables 1-2
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Supplementary Method, Reference, Figures 1-8, Tables 1-2
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 3 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s [parental, Gnaq-/-, and Gnaq-/- cells introduced with Gnaq (Gnaq-/- + Gnaq)]. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 1E. Images were acquired every 3 seconds for 15 minutes. From left to right: parental melanoma, Gnaq-/- melanoma, and Gnaq-/- melanoma cells introduced with Gnaq (Gnaq-/- + Gnaq). Genetic ablation of Gnaq abolished active Ca2+ transients observed in parental cells, which was restored by the introduction of Gnaq in Gnaq-/- melanoma. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 3 Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s [parental, Gnaq-/-, and Gnaq-/- cells introduced with Gnaq (Gnaq-/- + Gnaq)]. from Intravital Imaging Identifies the VEGF–TXA2 Axis as a Critical Promoter of PGE2 Secretion from Tumor Cells and Immune Evasion
Intravital imaging of BrafV600E melanoma cells expressing GCaMP6s. Images represent the fold increase in fluorescence intensity shown in IMD mode as in Figure 1E. Images were acquired every 3 seconds for 15 minutes. From left to right: parental melanoma, Gnaq-/- melanoma, and Gnaq-/- melanoma cells introduced with Gnaq (Gnaq-/- + Gnaq). Genetic ablation of Gnaq abolished active Ca2+ transients observed in parental cells, which was restored by the introduction of Gnaq in Gnaq-/- melanoma. Scale bar = 60 µm. Times are shown in minutes (m) and seconds (s).